BioSyent Announces Renewal of Normal Course Issuer Bid
16 déc. 2024 08h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted...
BioSyent Releases Financial Results for Q3 and YTD 2024
20 nov. 2024 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended...
BioSyent Declares Fourth Quarter 2024 Dividend
20 nov. 2024 07h55 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024
13 nov. 2024 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent Announces Agreement to Purchase Tibelia® (tibolone) Assets
20 sept. 2024 09h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has...
BioSyent Releases Financial Results for Q2 and H1 2024
26 août 2024 16h45 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30,...
BioSyent Declares Third Quarter 2024 Dividend
26 août 2024 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent In-Licenses Endocrinology Product for Canada
12 juin 2024 09h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc....
BioSyent Releases Financial Results for Q1 2024
16 mai 2024 18h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights...
BioSyent Declares Second Quarter 2024 Dividend
16 mai 2024 18h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend...